Cargando…

Mortality Risk Prediction Dynamics After Heart Failure Treatment Optimization: Repeat Risk Assessment Using Online Risk Calculators

OBJECTIVES: Heart failure (HF) management has significantly improved over the past two decades, leading to better survival. This study aimed to assess changes in predicted mortality risk after 12 months of management in a multidisciplinary HF clinic. MATERIALS AND METHODS: Out of 1,032 consecutive H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Codina, Pau, Zamora, Elisabet, Levy, Wayne C., Revuelta-López, Elena, Borrellas, Andrea, Spitaleri, Giosafat, Cediel, Germán, Ruiz-Cueto, María, Cañedo, Elena, Santiago-Vacas, Evelyn, Domingo, Mar, Buchaca, David, Subirana, Isaac, Santesmases, Javier, de la Espriella, Rafael, Nuñez, Julio, Lupón, Josep, Bayes-Genis, Antoni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039357/ https://www.ncbi.nlm.nih.gov/pubmed/35498033 http://dx.doi.org/10.3389/fcvm.2022.836451

Ejemplares similares

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
por: Lupón, Josep, et al.
Publicado: (2021)

Gender-Related Differences in Heart Failure Biomarkers
por: Cediel, Germán, et al.
Publicado: (2021)

Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension
por: Codina, Pau, et al.
Publicado: (2022)

Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence
por: Bayes-Genis, Antoni, et al.
Publicado: (2021)

Cause of Death in Heart Failure Based on Etiology: Long-Term Cohort Study of All-Cause and Cardiovascular Mortality
por: Spitaleri, Giosafat, et al.
Publicado: (2022)

Advanced remote care for heart failure in times of COVID-19 using an implantable pulmonary artery pressure sensor: the new normal
por: Bayes-Genis, Antoni, et al.
Publicado: (2020)

Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018
por: Spitaleri, Giosafat, et al.
Publicado: (2021)

Quality of life in patients with heart failure and improved ejection fraction: one‐year changes and prognosis
por: Zamora, Elisabet, et al.
Publicado: (2022)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Lung ultrasound in outpatients with heart failure: the wet‐to‐dry HF study
por: Domingo, Mar, et al.
Publicado: (2021)

Pirfenidone as a novel cardiac protective treatment
por: Aimo, Alberto, et al.
Publicado: (2021)

Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline
por: Julián, María Teresa, et al.
Publicado: (2020)

Destination Therapy with Left Ventricular Assist Devices in Non-transplant Centres: The Time is Right
por: Bayes-Genis, Antoni, et al.
Publicado: (2020)

Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator)
por: Lupón, Josep, et al.
Publicado: (2014)

Limited Value of Cystatin-C over Estimated Glomerular Filtration Rate for Heart Failure Risk Stratification
por: Zamora, Elisabet, et al.
Publicado: (2012)

Weight Loss in Obese Patients With Heart Failure
por: Zamora, Elisabet, et al.
Publicado: (2016)

Impact of diabetes on the predictive value of heart failure biomarkers
por: Alonso, Nuria, et al.
Publicado: (2016)

Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus
por: Rodríguez-Calvo, Ricardo, et al.
Publicado: (2023)

Biomarkers to Improve Decision-making in Acute Heart Failure
por: de la Espriella, Rafael, et al.
Publicado: (2023)

Lung ultrasound and biomarkers in primary care: Partners for a better management of patients with heart failure?
por: Domingo, Mar, et al.
Publicado: (2020)

Circulating monocyte subsets and heart failure prognosis
por: Elchinova, Elena, et al.
Publicado: (2018)

Caval Valve Implantation (CAVI): An Emerging Therapy for Treating Severe Tricuspid Regurgitation
por: Abdul-Jawad Altisent, Omar, et al.
Publicado: (2021)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)

Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction
por: Gastelurrutia, Paloma, et al.
Publicado: (2018)

Rehospitalization burden and morbidity risk in patients with heart failure with mid‐range ejection fraction
por: Santas, Enrique, et al.
Publicado: (2020)

The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations
por: Núñez, Julio, et al.
Publicado: (2021)

Impact of a ‘stent for life’ initiative on post‐ST elevation myocardial infarction heart failure: a 15 year heart failure clinic experience
por: Bayes‐Genis, Antoni, et al.
Publicado: (2017)

Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients
por: Pacho, Cristina, et al.
Publicado: (2018)

Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study
por: Revuelta‐López, Elena, et al.
Publicado: (2020)

Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction
por: Santas, Enrique, et al.
Publicado: (2020)

Determination of HLA‐A, ‐B, ‐C, ‐DRB1 and ‐DQB1 allele and haplotype frequencies in heart failure patients
por: Roura, Santiago, et al.
Publicado: (2019)

Nutritional Status According to the GLIM Criteria in Patients with Chronic Heart Failure: Association with Prognosis
por: Joaquín, Clara, et al.
Publicado: (2022)

Can Natriuretic Peptides be Used to Guide Therapy?
por: Bayes-Genis, Antoni, et al.
Publicado: (2016)

Compelling Benefit of Soluble Suppression of Tumorigenicity‐2 in Post–Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic
por: Díez, Javier, et al.
Publicado: (2017)

Prognostic Value of New‐Generation Troponins in ST‐Segment–Elevation Myocardial Infarction in the Modern Era: The RUTI‐STEMI Study
por: Cediel, Germán, et al.
Publicado: (2017)

Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction
por: Miñana, Gema, et al.
Publicado: (2022)

Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
por: Iborra-Egea, Oriol, et al.
Publicado: (2019)

Potential role for clinical calibration to increase engagement with and application of home telemonitoring: a report from the HeartCycle programme
por: Gastelurrutia, Paloma, et al.
Publicado: (2016)

Multi-Biomarker Profiling and Recurrent Hospitalizations in Heart Failure
por: Bayes-Genis, Antoni, et al.
Publicado: (2016)

Circulating miR-1254 predicts ventricular remodeling in patients with ST-Segment-Elevation Myocardial Infarction: A cardiovascular magnetic resonance study
por: de Gonzalo-Calvo, David, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9sgku5a2psemiromsjet2vq5ck